Table 2.
Genotype frequencies of methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TS) gene polymorphisms in osteoporosis.
| Genotypes | Control | Case | ORs Adjusted Age, HTN, and DM (95% CI) 1 | p 2 | p 5 | OVCF | ORs Adjusted Age, HTN, and DM (95% CI) 1 | p 3 | p 5 | Non-OVCF | ORs Adjusted Age, HTN, and DM (95% CI) 1 | p 4 | p 5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 158) | (n = 143) | (n = 74) | (n = 69) | ||||||||||
| MTHFR 2572C>A | |||||||||||||
| CC | 103 (65.2) | 111 (77.6) | 1.000 (reference) | 62 (83.8) | 1.000 (reference) | 49 (71.0) | 1.000 (reference) | ||||||
| CA | 52 (32.9) | 29 (20.3) | 0.494 (0.285–0.857) | 0.012 | 0.024 | 11 (14.9) | 0.382 (0.179–0.813) | 0.013 | 0.026 | 18 (26.1) | 0.682 (0.354–1.314) | 0.253 | 0.337 |
| AA | 3 (1.9) | 3 (2.1) | N/A | N/A | 1 (1.4) | N/A | N/A | 2 (2.9) | N/A | N/A | |||
| Dominant (CC vs. CA+AA) | 0.516 (0.303–0.880) | 0.015 | 0.030 | 0.397 (0.191–0.825) | 0.013 | 0.026 | 0.709 (0.375–1.340) | 0.29 | 0.387 | ||||
| Recessive (CC+CA vs. AA) | N/A | N/A | N/A | N/A | N/A | N/A | |||||||
| HWE-P | 0.288 | 0.885 | |||||||||||
| MTHFR 4869C>G | |||||||||||||
| CC | 135 (85.4) | 132 (92.3) | 1.000 (reference) | 68 (91.9) | 1.000 (reference) | 64 (92.8) | 1.000 (reference) | ||||||
| CG | 23 (14.6) | 11 (7.7) | 0.454 (0.201–1.026) | 0.058 | 0.077 | 6 (8.1) | 0.503 (0.181–1.395) | 0.187 | 0.187 | 5 (7.2) | 0.487 (0.173–1.367) | 0.172 | 0.337 |
| GG | 0 (0.0) | 0 (0.0) | N/A | N/A | 0 (0.0) | N/A | N/A | 0 (0.0) | N/A | N/A | |||
| Dominant (CC vs. CG+GG) | 0.454 (0.201–1.026) | 0.058 | 0.077 | 0.503 (0.181–1.395) | 0.187 | 0.187 | 0.487 (0.173–1.367) | 0.172 | 0.344 | ||||
| Recessive (CC+CG vs. GG) | N/A | N/A | N/A | N/A | N/A | N/A | |||||||
| HWE-P | 0.324 | 0.632 | |||||||||||
| TS 1100C>T | |||||||||||||
| CC | 92 (58.2) | 95 (66.4) | 1.000 (reference) | 56 (75.7) | 1.000 (reference) | 39 (56.5) | 1.000 (reference) | ||||||
| CT | 58 (36.7) | 40 (28.0) | 0.886 (0.314–2.497) | 0.819 | 0.819 | 17 (23.0) | 0.492 (0.252–0.961) | 0.038 | 0.051 | 23 (33.3) | 0.952 (0.503–1.804) | 0.881 | 0.887 |
| TT | 8 (5.1) | 8 (5.6) | 0.625 (0.215–1.820) | 0.389 | 0.389 | 1 (1.4) | 0.249 (0.030–2.067) | 0.198 | 0.198 | 7 (10.1) | 2.417 (0.784–7.454) | 0.125 | 0.125 |
| Dominant (CC vs. CT+TT) | 0.781 (0.283–2.158) | 0.634 | 0.634 | 0.462 (0.241–0.886) | 0.02 | 0.027 | 1.114 (0.615–2.021) | 0.721 | 0.721 | ||||
| Recessive (CC+CT vs. TT) | 1.355 (0.835–2.200) | 0.219 | 0.219 | 0.303 (0.037–2.485) | 0.266 | 0.266 | 2.433 (0.817–7.245) | 0.11 | 0.110 | ||||
| HWE-P | 0.497 | 0.280 | |||||||||||
| TS 1170A>G | |||||||||||||
| AA | 64 (40.5) | 104 (72.7) | 1.000 (reference) | 48 (64.9) | 1.000 (reference) | 56 (81.2) | 1.000 (reference) | ||||||
| AG | 76 (48.1) | 34 (23.8) | 0.276 (0.165–0.460) | <0.0001 | 0.0004 | 24 (32.4) | 0.413 (0.221–0.774) | 0.006 | 0.024 | 10 (14.5) | 0.147 (0.068–0.320) | <0.0001 | 0.0004 |
| GG | 18 (11.4) | 5 (3.5) | 0.168 (0.059–0.475) | 0.001 | 0.002 | 2 (2.7) | 0.086 (0.011–0.672) | 0.019 | 0.038 | 3 (4.3) | 0.137 (0.035–0.527) | 0.004 | 0.008 |
| Dominant (AA vs. AG+GG) | 0.255 (0.157–0.415) | <0.0001 | 0.0004 | 0.354 (0.192–0.653) | 0.001 | 0.004 | 0.146 (0.072–0.298) | <0.0001 | 0.0004 | ||||
| Recessive (AA+AG vs. GG) | 0.281 (0.101–0.778) | 0.015 | 0.030 | 0.129 (0.017–0.994) | 0.049 | 0.098 | 0.275 (0.075–1.007) | 0.051 | 0.102 | ||||
| HWE-P | 0.520 | 0.267 |
OR, odd ratio; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus; HWE, Hardy–Weinberg equilibrium; N/A, not applicable. 1 The odds ratio (OR) adjusted on the basis of risk factors, such as age, hypertension, diabetes mellitus; 2 p-value was compared between osteoporosis and control groups; 3 p-value was compared between OVCF and control groups; 4 p-value was compared between non-OVCF and control groups; 5 p-value calculated by false discovery rate test.